Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
age-related macular degeneration
Pharma
After 3 CRLs, FDA approves Outlook's AMD drug Lytenava
The FDA has approved Outlook's Lytenava for wet age-related macular degeneration. The compound has been used off-label in the indication for two decades.
Kevin Dunleavy
Jul 27, 2026 11:51am
Bayer found to have discredited industry after Roche row
Mar 13, 2026 11:45am
Outlook stock plummets as FDA again snubs wet AMD drug
Aug 28, 2025 10:55am
FDA denies Regeneron's bid for dosage flexibility on Eylea
Apr 21, 2025 8:45am
JPM25: Regeneron has few answers for declining sales of Eylea HD
Jan 14, 2025 10:25am
Asian patients with PCV show improvement with Roche's Vabysmo
Nov 22, 2024 7:00am
